CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOS (BIACA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jeffrey J. Wood, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00280670
First received: January 20, 2006
Last updated: March 28, 2012
Last verified: March 2012

January 20, 2006
March 28, 2012
January 2005
August 2008   (final data collection date for primary outcome measure)
  • Score on anxiety diagnostic interview after treatment or waitlist [ Time Frame: post-treatment ] [ Designated as safety issue: No ]
  • Score on anxiety rating scale after treatment or waitlist [ Time Frame: post-treatment ] [ Designated as safety issue: No ]
  • score on anxiety diagnostic interview after treatment or waitlist
  • score on anxiety rating scale after treatment or waitlist
Complete list of historical versions of study NCT00280670 on ClinicalTrials.gov Archive Site
  • Score on daily living skills rating scale after treatment or waitlist [ Time Frame: post-treatment ] [ Designated as safety issue: No ]
  • Score on children's social functioning and service use after treatment or waitlist [ Time Frame: post-treatment ] [ Designated as safety issue: No ]
  • score on daily living skills rating scale after treatment or waitlist
  • score on children's social functioning and service use after treatment or waitlist
Not Provided
Not Provided
 
CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOS
Not Provided

This study is designed to examine the efficacy of a cognitive behavioral therapy (CBT) program for treating anxiety symptoms, social problems, and adaptive behavior deficits in children with autism spectrum disorders.

Anxiety disorders are commonly diagnosed in children with autism, Asperger syndrome (AS), and pervasive developmental disorder not otherwise specified (PDD-NOS). Anxiety disorders contribute to children's functional impairment over and above the functional deficits attributable to autism, AS, and PDD-NOS. Thus, investigators have called for the development of anxiety treatments for this population (Attwood, 2003). Cognitive behavioral therapy (CBT) has been found to be efficacious for anxiety disorders in typically developing children. This pilot study will advance the field by providing an estimate of the treatment effects of CBT for anxiety disorders among children with autism, AS, or PDD-NOS. The sample will include 20 children aged 7-11 years with autism, AS, or PDD-NOS and a comorbid anxiety disorder. Children will be randomly assigned to immediate treatment or a 3-month waitlist. The manualized CBT program includes traditional anxiety treatment components including coping skills training (e.g., cognitive restructuring), in vivo exposure, operant procedures, and parent training. Additional treatment components have been added to enhance intervention response in children with AS or PDD-NOS, including emotion education, social skills/friendship skills training, and peer tutoring/mentoring modules. Trained graduate students with expertise in CBT and developmental disabilities will serve as therapists. Treatment fidelity will be checked using a session-by-session adherence checklist. Treatment acceptability and consumer satisfaction will be assessed at posttreatment, providing guidance on the extent to which the manual will need to be revised. Multiple measures of children's anxiety, including a structured diagnostic interview administered by an independent evaluator, will comprise the primary outcomes. Children's social functioning, adaptive behavior, and service use will also be assessed to determine if CBT can affect relevant distal outcomes. By comparing outcomes for children in the immediate treatment group versus those in the waitlist group, we will estimate effect sizes of CBT for this population. Subsequently, power analyses will be conducted in planning for a larger clinical trial. This study could contribute to public health efforts to address the mental health needs of the rising number of children diagnosed with autism-spectrum disorders. If CBT is found to be efficacious, it will be the first evidence-based psychological treatment to be successfully adapted for children with autism, AS, and PDD-NOS.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Autistic Disorder
  • Asperger Syndrome
  • Anxiety Disorders
Behavioral: Cognitive-behavioral therapy
Cognitive behavioral therapy for children with autism and anxiety.
  • Experimental: Cognitive Behavioral Therapy
    Intervention: Behavioral: Cognitive-behavioral therapy
  • No Intervention: Waitlist
Wood JJ, Drahota A, Sze K, Har K, Chiu A, Langer DA. Cognitive behavioral therapy for anxiety in children with autism spectrum disorders: a randomized, controlled trial. J Child Psychol Psychiatry. 2009 Mar;50(3):224-34.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
August 2009
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 7 - 11 years of age
  • Meet research criteria for a diagnosis of Asperger Syndrome or PDD-NOS
  • Meet DSM-IV criteria for one of the following anxiety disorders: Separation Anxiety Disorder, Social Phobia, Obsessive-Compulsive Disorder
  • If taking medication, have maintained a stable dose for 1 month prior to baseline assessment

Exclusion Criteria:

  • Child has an IQ of less than 70
  • Begin taking new medication(s) or current medication dose changes either (1) less than 1 month prior to baseline assessment, or (2) during the study period
  • For any reason the child or parents appear unable to participate in the treatment program
Both
7 Years to 11 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00280670
R03-MH075806-01
Yes
Jeffrey J. Wood, University of California, Los Angeles
University of California, Los Angeles
Not Provided
Principal Investigator: Jeffrey J Wood, Ph.D. University of California, Los Angeles
University of California, Los Angeles
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP